Literature DB >> 28888103

Using CRISPR-Cas systems as antimicrobials.

David Bikard1, Rodolphe Barrangou2.   

Abstract

Although CRISPR-Cas systems naturally evolved to provide adaptive immunity in bacteria and archaea, Cas nucleases can be co-opted to target chromosomal sequences rather than invasive genetic elements. Although genome editing is the primary outcome of self-targeting using CRISPR-based technologies in eukaryotes, self-targeting by CRISPR is typically lethal in bacteria. Here, we discuss how DNA damage introduced by Cas nucleases in bacteria can efficiently and specifically lead to plasmid curing or drive cell death. Specifically, we discuss how various CRISPR-Cas systems can be engineered and delivered using phages or phagemids as vectors. These principles establish CRISPR-Cas systems as potent and programmable antimicrobials, and open new avenues for the development of CRISPR-based tools for selective removal of bacterial pathogens and precise microbiome composition alteration.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2017        PMID: 28888103     DOI: 10.1016/j.mib.2017.08.005

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  25 in total

Review 1.  Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease.

Authors:  Jin Ah Cho; Daniel J F Chinnapen
Journal:  J Microbiol       Date:  2018-02-28       Impact factor: 3.422

Review 2.  CRISPR-Cas Biology and Its Application to Infectious Diseases.

Authors:  Jeffrey R Strich; Daniel S Chertow
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

3.  Synergistic Quinolone Sensitization by Targeting the recA SOS Response Gene and Oxidative Stress.

Authors:  S Diaz-Diaz; E Recacha; J Machuca; A García-Duque; F Docobo-Pérez; J Blázquez; A Pascual; J M Rodríguez-Martínez
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

4.  Using an Endogenous CRISPR-Cas System for Genome Editing in the Human Pathogen Clostridium difficile.

Authors:  Anna Maikova; Victor Kreis; Anaïs Boutserin; Konstantin Severinov; Olga Soutourina
Journal:  Appl Environ Microbiol       Date:  2019-10-01       Impact factor: 4.792

5.  CRISPR-Cas is associated with fewer antibiotic resistance genes in bacterial pathogens.

Authors:  Elizabeth Pursey; Tatiana Dimitriu; Fernanda L Paganelli; Edze R Westra; Stineke van Houte
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2021-11-29       Impact factor: 6.237

6.  Investigating the Genomic Background of CRISPR-Cas Genomes for CRISPR-Based Antimicrobials.

Authors:  Hyunjin Shim
Journal:  Evol Bioinform Online       Date:  2022-06-08       Impact factor: 2.031

Review 7.  CRISPR: The Multidrug Resistance Endgame?

Authors:  Arpit Shukla; Nistha Jani; Monika Polra; Anushree Kamath; Dhara Patel
Journal:  Mol Biotechnol       Date:  2021-05-21       Impact factor: 2.695

8.  IncC conjugative plasmids and SXT/R391 elements repair double-strand breaks caused by CRISPR-Cas during conjugation.

Authors:  David Roy; Kevin T Huguet; Frédéric Grenier; Vincent Burrus
Journal:  Nucleic Acids Res       Date:  2020-09-18       Impact factor: 16.971

Review 9.  Molecular Mechanisms Influencing Bacterial Conjugation in the Intestinal Microbiota.

Authors:  Kevin Neil; Nancy Allard; Sébastien Rodrigue
Journal:  Front Microbiol       Date:  2021-06-04       Impact factor: 5.640

10.  CRISPR-Cas antimicrobials: Challenges and future prospects.

Authors:  Elizabeth Pursey; David Sünderhauf; William H Gaze; Edze R Westra; Stineke van Houte
Journal:  PLoS Pathog       Date:  2018-06-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.